World Health Organization. WHO Guidelines for Malaria, 3 June 2022. Report No. WHO/UCN/GMP/2022.01 Rev.2 (World Health Organization, 2022).
Esu, E. B., Oringanje, C. & Meremikwu, M. M. Intermittent preventive treatment for malaria in infants. Cochrane Database Syst. Rev. 7 (Cd011525). https://doi.org/10.1002/14651858.CD011525.pub3 (2021).
Ross, A., Maire, N., Sicuri, E., Smith, T. & Conteh, L. Determinants of the cost-effectiveness of intermittent preventive treatment for malaria in infants and children. PLOS ONE. 6, e18391. https://doi.org/10.1371/journal.pone.0018391 (2011).
Ross, A. et al. Modelling the epidemiological impact of intermittent preventive treatment against malaria in infants. PLOS ONE. 3, e2661. https://doi.org/10.1371/journal.pone.0002661 (2008).
World Health Organization. WHO Technical Consultation To Review the Role of Drugs in Malaria Prevention for People Living in Endemic Settings (Malaria Policy Advisory Committee Meeting, 2019). Report No. WHO/UHC/GMP/MPAC/2020.03.
World Health Organization. World malaria report 2009. (Geneva: World Health Organization. (2009). https://www.who.int/publications/i/item/9789241563901.
Benn, C. S. & Aaby, P. Does IPTi decrease malaria morbidity but not mortality? Lancet 380, 958–960. https://doi.org/10.1016/S0140-6736(12)61184-2 (2012).
Schellenberg, D., Cisse, B. & Menendez, C. The IPTi consortium: research for policy and action. Trends Parasitol. 22, 296–300. https://doi.org/10.1016/j.pt.2006.05.006 (2006). https://doi.org/https://doi.org/
Unitaid & Perennial Malaria Chemoprevention (PMC). : The Unitaid IPTi + Project addressing the gap between WHO guidance and country implementation. (RBM MiP Annual Meeting: Accra, Ghana. (2022). https://endmalaria.org/sites/default/files/3b%20J.Kouakou_IPTi%2B%20Project.pdf.
Unitaid. The plus project reducing morbidity and mortality due to malaria and anemia in children under 2. (2023). https://www.psi.org/project/plusproject/.
World Health Organisation. WHO Guidelines for Malaria, 16 October 2023. Report No. WHO/UCN/GMP/2023.01 Rev.1 (World Health Organization, 2023).
Kobbe, R. et al. A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants. Clin. Infect. Dis. 45, 16–25. https://doi.org/10.1086/518575 (2007).
Mockenhaupt, F. P. et al. Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in Northern Ghana. Antimicrob. Agents Chemother. 51, 3273–3281. https://doi.org/10.1128/aac.00513-07 (2007).
Grobusch, M. P. et al. Intermittent preventive treatment against malaria in infants in Gabon–a randomized, double-blind, placebo-controlled trial. J. Infect. Dis. 196, 1595–1602. https://doi.org/10.1086/522160 (2007).
Runge, M. et al. Perennial malaria chemoprevention with and without malaria vaccination to reduce malaria burden in young children: a modelling analysis. Malar. J. 22, 133. https://doi.org/10.1186/s12936-023-04564-9 (2023).
Bigira, V. et al. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med. 11, e1001689. https://doi.org/10.1371/journal.pmed.1001689 (2014).
World Health Organization. Technical consultation on the malaria rebound phenomenon: report on a virtual meeting, 22–23 March 2022. (Geneva: World Health Organization. (2022). https://apps.who.int/iris/handle/10665/361710.
Greenwood, B. et al. Resurgent and delayed malaria. Malar. J. 21, 77. https://doi.org/10.1186/s12936-022-04098-6 (2022).
Schellenberg, D. et al. Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 365, 1481–1483. https://doi.org/10.1016/s0140-6736(05)66418-5 (2005).
Chandramohan, D. et al. Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ (Clinical Res. ed.). 331, 727–733. https://doi.org/10.1136/bmj.331.7519.727 (2005).
Penny, M. A. et al. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet 387, 367–375. https://doi.org/10.1016/s0140-6736(15)00725-4 (2016).
Águas, R., Lourenço, J. M. L., Gomes, M. G. M. & White, L. J. The impact of IPTi and IPTc interventions on malaria clinical Burden – In Silico perspectives. PLOS ONE. 4, e6627. https://doi.org/10.1371/journal.pone.0006627 (2009).
World Health Organization. WHO malaria terminology 2021 update. Report No. WHO/HTM/GMP/2016.6, (Geneva: World Health Organization. (2021). https://apps.who.int/iris/handle/10665/349442.
Omondi, C. J. et al. Perennial transmission of malaria in the low altitude areas of Baringo County, Kenya. Malar. J. 16, 257. https://doi.org/10.1186/s12936-017-1904-y (2017).
Ashley, E. A. & Yeka, A. Seasonal malaria chemoprevention: closing the know-do gap. Lancet 396, 1778–1779. https://doi.org/10.1016/s0140-6736(20)32525-3 (2020).
Plowe, C. V. Malaria chemoprevention and drug resistance: a review of the literature and policy implications. Malar. J. 21, 104. https://doi.org/10.1186/s12936-022-04115-8 (2022).
Steinhardt Laura. Summary of intermittent preventive treatment in infants (IPTi) contextual factors. Section 4.2.2 Perennial malaria chemoprevention (PMC). In WHO Guidelines for malaria, 3 June 2022. (2022).
Macete, E. et al. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. J. Infect. Dis. 194, 276–285. https://doi.org/10.1086/505431 (2006).
Burgert, L., Reiker, T., Golumbeanu, M., Möhrle, J. J. & Penny, M. A. Model-informed target product profiles of long-acting-injectables for use as seasonal malaria prevention. PLOS Glob Public. Health. 2, e0000211. https://doi.org/10.1371/journal.pgph.0000211 (2022).
Masserey, T., Lee, T., Kelly, S. L., Hastings, I. M. & Penny, M. A. Seasonal malaria chemoprevention and the spread of Plasmodium falciparum quintuple mutant parasites resistant to sulfadoxine-pyrimethamine: a modelling study. Lancet Microbe. 5, 100892. https://doi.org/10.1016/S2666-5247(24)00115-0 (2024).
Mahaman Moustapha, L. et al. Evidence that seasonal malaria chemoprevention with SPAQ influences blood and pre-erythrocytic stage antibody responses of Plasmodium falciparum infections in Niger. Malar. J. 20, 1. https://doi.org/10.1186/s12936-020-03550-9 (2021).
Gosling, R. D., Carneiro, I. & Chandramohan, D. Intermittent preventive treatment of malaria in infants: how does it work and where will it work? Trop. Med. Int. Health. 14, 1003–1010. https://doi.org/10.1111/j.1365-3156.2009.02303.x (2009).
de Kock, M. et al. Population Pharmacokinetic properties of sulfadoxine and pyrimethamine: a pooled analysis to inform optimal dosing in African children with uncomplicated malaria. Antimicrob. Agents Chemother. 62, e01370-17. https://doi.org/10.1128/aac.01370-17 (2018).
Masserey, T. et al. The influence of biological, epidemiological, and treatment factors on the establishment and spread of drug-resistant plasmodium falciparum. eLife 11, e77634. https://doi.org/10.7554/eLife.77634 (2022).
Delves, M. et al. The activities of current antimalarial drugs on the life cycle stages of plasmodium: a comparative study with human and rodent parasites. PLoS Med. 9, e1001169. https://doi.org/10.1371/journal.pmed.1001169 (2012).
Masserey, T., Braunack-Mayer, L., Miller, R. S., Möhrle, J. J. & Penny, M. A. A roadmap for Understanding sulfadoxine-pyrimethamine in malaria chemoprevention. Parasitology, Published online 2025:1–10. https://doi.org/10.1017/S0031182025000071 (2025).
Cairns, M. et al. Duration of protection against malaria and anaemia provided by intermittent preventive treatment in infants in Navrongo, Ghana. PloS One. 3, e2227–e2227. https://doi.org/10.1371/journal.pone.0002227 (2008).
Kelly, S. L., Malinga, J. & Penny, M. A. Comparing modelled impact and cost-effectiveness estimates for the RTS,S/AS01 malaria vaccine with evaluation results observed in phased pilot introductions. (2024). https://cdn.who.int/media/docs/default-source/immunization/sage/vpp-background-documents/malaria/path_final-report-on-vaccine-impact-and-cost-effectiveness-estimates6d0e5362-c947-4ff8-b0d5-1c485c0ed8ce.pdf?sfvrsn=371c20a_1.
Gunda, R. & Chimbari, M. J. Cost-effectiveness analysis of malaria interventions using disability adjusted life years: a systematic review. Cost Eff. Resour. Alloc. 15, 10. https://doi.org/10.1186/s12962-017-0072-9 (2017).
Conteh, L. et al. Costs and cost-effectiveness of malaria control interventions: a systematic literature review. Value Health. 24, 1213–1222. https://doi.org/10.1016/j.jval.2021.01.013 (2021).
Braunack-Mayer, L. et al. Design and selection of drug properties to increase the public health impact of next-generation seasonal malaria chemoprevention: a modelling study. Lancet Glob Health. 12, e478–e490. https://doi.org/10.1016/S2214-109X(23)00550-8 (2024).
White, N. J. Intermittent presumptive treatment for malaria. PLoS Med. 2, e3. https://doi.org/10.1371/journal.pmed.0020003 (2005).
Desai, M. et al. Impact of sulfadoxine-pyrimethamine resistance on effectiveness of intermittent preventive therapy for malaria in pregnancy at clearing infections and preventing low birth weight. Clin. Infect. Dis. 62, 323–333. https://doi.org/10.1093/cid/civ881 (2016).
Nankabirwa, J. et al. Efficacy, safety, and tolerability of three regimens for prevention of malaria: a randomized, placebo-controlled trial in Ugandan schoolchildren. PLoS One. 5, e13438. https://doi.org/10.1371/journal.pone.0013438 (2010).
Lahuerta, M. et al. Evaluation of health system readiness and coverage of intermittent preventive treatment of malaria in infants (IPTi) in Kambia district to inform National scale-up in Sierra Leone. Malar. J. 20, 74–74. https://doi.org/10.1186/s12936-021-03615-3 (2021).
Marseille, E., Larson, B., Kazi, D. S., Kahn, J. G. & Rosen, S. Thresholds for the cost–effectiveness of interventions: alternative approaches. Bull. World Health Organ. 93, 118–124. https://doi.org/10.2471/BLT.14.138206 (2014).
Agusto, F. B. & IM, E. L. Optimal control and cost-effective analysis of malaria/visceral leishmaniasis co-infection. PLoS One. 12, e0171102. https://doi.org/10.1371/journal.pone.0171102 (2017).
Bertram, M. Y. & Edejer, T. T. T. Introduction to the Special Issue on The World Health Organization Choosing Interventions That Are Cost-Effective (WHO-CHOICE) Update. IJHPM 10, 670–672 (2021). https://doi.org/10.34172/ijhpm.2021.105
Golumbeanu, M. et al. Leveraging mathematical models of disease dynamics and machine learning to improve development of novel malaria interventions. Infect. Dis. Poverty. 11, 61. https://doi.org/10.1186/s40249-022-00981-1 (2022).
Reiker, T. et al. Emulator-based bayesian optimization for efficient multi-objective calibration of an individual-based model of malaria. Nat. Commun. 12, 7212. https://doi.org/10.1038/s41467-021-27486-z (2021).
Smith, T. et al. Mathematical modeling of the impact of malaria vaccines on the clinical epidemiology and natural history of Plasmodium falciparum malaria: overview. Am. J. Trop. Med. Hyg. 75, 1–10. https://doi.org/10.4269/ajtmh.2006.75.2_suppl.0750001 (2006).
Smith, T. et al. Ensemble modeling of the likely public health impact of a pre-erythrocytic malaria vaccine. PLoS Med. 9, e1001157. https://doi.org/10.1371/journal.pmed.1001157 (2012).
Molineaux, L. et al. Plasmodium falciparum parasitaemia described by a new mathematical model. Parasitology 122, 379–391. https://doi.org/10.1017/S0031182001007533 (2001).
Nu Htay, M., Hastings, I., Hodel, E. & Kay, K. Effectiveness of intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine: an in Silico Pharmacological model. Asian Pac. J. Trop. Med. 13, 366–374. https://doi.org/10.4103/1995-7645.289441 (2020).
Kay, K. & Hastings, I. M. Improving pharmacokinetic-pharmacodynamic modeling to investigate anti-infective chemotherapy with application to the current generation of antimalarial drugs. PLOS Comput. Biol. 9, e1003151. https://doi.org/10.1371/journal.pcbi.1003151 (2013).
Okell, L. C. et al. Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis. Nat. Commun. 5, 5606. https://doi.org/10.1038/ncomms6606 (2014).
Wilcox, R. R. in In Introduction To Robust Estimation and Hypothesis Testing (Fifth Edition). 253–350 (eds Wilcox, R. R.) (Academic, 2022).
Nhama, A. et al. In vivo efficacy and safety of artemether–lumefantrine and amodiaquine–artesunate for uncomplicated plasmodium falciparum malaria in Mozambique, 2018. Malar. J. 20 (390). https://doi.org/10.1186/s12936-021-03922-9 (2021).
Russo, G. & McPake, B. Medicine prices in urban Mozambique: a public health and economic study of pharmaceutical markets and price determinants in low-income settings. Health Policy Plan. 25, 70–84. https://doi.org/10.1093/heapol/czp042 (2009).
World Health Organization. Regional Strategic Plan for Immunization 2014–2020. (Regional Office for Africa:World Health Organization, (2015). https://iris.who.int/handle/10665/204373.
Berzosa, P. et al. Comparison of three diagnostic methods (microscopy, RDT, and PCR) for the detection of malaria parasites in representative samples from Equatorial Guinea. Malar. J. 17, 333. https://doi.org/10.1186/s12936-018-2481-4 (2018).
Griffin, J. et al. Protective efficacy of intermittent preventive treatment of malaria in infants (ipti) using sulfadoxine-pyrimethamine and parasite resistance. PLoS ONE. 5 (9). https://doi.org/10.1371/journal.pone.0012618 (2010).
von Seidlein, L. et al. A randomized controlled trial of Artemether/benflumetol, a new antimalarial and Pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria in African children. Am. J. Trop. Med. Hyg. 58, 638–644. https://doi.org/10.4269/ajtmh.1998.58.638 (1998).
